Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137296 | 0.93 | TSHR (0.42) | TSHRHSD11B1 | |
| SCHEMBL5135432 | 0.92 | MEN1 (0.36) | TSHR | |
| SCHEMBL4768491 | 0.91 | TSHR (0.41) | TSHRHSD11B1C5AR1 | |
| SCHEMBL5137395 | 0.89 | TSHR (0.42) | TSHRHSD11B1C5AR1 | |
| SCHEMBL5072278 | 0.87 | TSHR (0.51) | TSHRHSD11B1C5AR1 | |
| SCHEMBL4763697 | 0.87 | C5AR1 (0.53) | TSHRC5AR1 | |
| SCHEMBL5135325 | 0.87 | TSHR (0.41) | TSHRHSD11B1 | |
| SCHEMBL5136720 | 0.87 | TSHR (0.44) | TSHRHSD11B1C5AR1 | |
| SCHEMBL5137696 | 0.86 | TSHR (0.41) | TSHRHSD11B1C5AR1 | |
| SCHEMBL5137316 | 0.86 | TSHR (0.45) | TSHRHSD11B1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | C3AR1, C5AR1, C5AR2 | TSHR 952/4885HSD11B1 4488/4885C5AR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.